共 42 条
- [41] Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients With Revised International Prognostic Scoring System Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes With Ring Sideroblasts Who Require Red Blood Cell Transfusions CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02)
- [42] Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes ( MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions BLOOD, 2019, 134